Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,607 signal articles · 118 in last 24h · 155,469 total before filter · latest 37m ago
118last 24h
855last 7d
146● bullish (7d)
90● bearish (7d)
214publishers
AllMacro191Earnings105M&A126Regulatory20Product22Analyst19
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
AstraZeneca breast cancer drug fails trial but Citi keeps 'buy' rating
Proactive11d agobullish
AstraZeneca breast cancer drug fails trial but Citi keeps 'buy' rating

AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental breast cancer drug camizestrant has failed a late-stage trial, though analysts at Citi say the setback does little to dent the company's prospects. Citi kept its 'buy' rating and £178 target price on the FTSE 100 pharmaceuticals group,...

3 Reasons to Avoid T and 1 Stock to Buy Instead
StockStory11d agobullish
3 Reasons to Avoid T and 1 Stock to Buy Instead

Over the last six months, AT&T’s shares have sunk to $26.05, producing a disappointing 6.1% loss - a stark contrast to the S&P 500’s 13.3% gain. This may have investors wondering how to approach the situation.

Hewlett Packard Enterprise (HPE) Surges 19% in a Week — What to Watch For Next?
Insider Monkey12d agobullish
Hewlett Packard Enterprise (HPE) Surges 19% in a Week — What to Watch For Next?

Hewlett Packard Enterprise (NYSE:HPE) grew its share price by 19.4 percent week-on-week amid the growth opportunities from continued investment outpour in the artificial intelligence sector, which pushed investors to increase their exposure to its stock. Investor optimism was supported by Oracle Corp.’s indication in an earnings call last week that it will continue to pour […]